Safety and efficacy of everolimus as a rescue therapy in autoimmune hepatitis: 12-months follow-up data
Background and objective: In autoimmune hepatitis (AIH), some patients fail to respond to first-line immunosuppression or develop treatment-related malignancies requiring alternative treatments. Rapamycin (mTOR) inhibitors may represent an alternative treatment strategy; however, long-term follow-up [for full text, please go to the a.m. URL]
Authors
- M Krawczyk
- C. Veltkamp
- H. H. Schmidt
- F. Seltsam
- M. Daniel
Institutions
- Essen University Hospital (DE)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2026-06-18
- DOI
- https://doi.org/10.3205/26vzmnrw129
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 0.00